SLC13A4 Antibody

What is SLC13A4 and why is it important in research?

SLC13A4 (also known as SUT1, Na(+)/sulfate cotransporter SUT-1, NaS2) functions as a sodium:sulfate symporter that mediates sulfate reabsorption in high endothelial venules (HEV). This protein plays a critical role in maintaining sulfate homeostasis, which is essential for numerous physiological processes. Research interest in SLC13A4 has grown significantly as TCGA database analyses have revealed its differential expression across various tumor types, particularly in head and neck squamous cell carcinoma (HNSCC), where it appears to have prognostic value. Investigating SLC13A4 is important because sulfate transporters and sulfate metabolism are implicated in multiple human diseases, including neurodevelopmental disorders, chondrodysplasias, and potentially cancer development .

What are the main characteristics of commercially available SLC13A4 antibodies?

Commercial SLC13A4 antibodies, such as rabbit polyclonal antibodies, typically recognize specific epitopes within the human SLC13A4 protein. For example, the antibody ab236619 targets a recombinant fragment protein within human SLC13A4 amino acids 100-300. These antibodies are usually validated for multiple applications including Western blotting (WB), immunohistochemistry on paraffin-embedded tissues (IHC-P), and immunocytochemistry/immunofluorescence (ICC/IF). The predicted molecular weight of SLC13A4 is approximately 69 kDa, which serves as an important reference point when validating antibody specificity in Western blot applications .

How can SLC13A4 antibodies be optimized for Western blot experiments?

For optimal Western blot results with SLC13A4 antibodies, researchers should implement the following methodological approach:

• Protein extraction: Use an efficient lysis buffer with protease inhibitors to preserve SLC13A4 integrity

• Protein quantification: Standardize loading to 20-30μg total protein per lane

• Gel separation: Utilize 8-10% SDS-PAGE gels for optimal separation around the 69 kDa range

• Transfer: Implement semi-dry or wet transfer with methanol-containing buffers for efficient transfer of this transmembrane protein

• Blocking: Use 5% non-fat milk or BSA in TBST for 1 hour at room temperature

• Primary antibody incubation: Dilute SLC13A4 antibody to 1/500 in blocking solution and incubate overnight at 4°C

• Detection: Use HRP-conjugated secondary antibodies (e.g., goat anti-rabbit IgG at 1/10,000 dilution) with appropriate chemiluminescent substrates

HEK-293T cell lysates have proven to be effective positive controls for SLC13A4 antibody validation in Western blot applications .

What tissues are most suitable for immunohistochemical analysis of SLC13A4 expression?

Based on validated research findings, placenta and testis tissues consistently demonstrate notable SLC13A4 expression and are recommended for immunohistochemical analysis. For optimal IHC-P protocol with SLC13A4 antibodies:

• Antigen retrieval: Perform heat-mediated antigen retrieval using citrate buffer (pH 6.0)

• Blocking: Apply 10% normal serum with 1% BSA in TBS for 2 hours

• Primary antibody: Dilute SLC13A4 antibody to 1/100 in blocking solution and incubate overnight at 4°C

• Detection: Utilize polymer-based detection systems with DAB chromogen

• Counterstaining: Apply hematoxylin for nuclear visualization

• Controls: Include both positive (placenta/testis) and negative controls (antibody diluent only)

When evaluating expression patterns, researchers should note that SLC13A4 demonstrates tissue-specific localization patterns, which can provide insights into functional roles in different cellular compartments .

How is SLC13A4 expression correlated with clinical features in HNSCC?

SLC13A4 expression demonstrates significant correlations with multiple clinical parameters in HNSCC patients. Key findings from TCGA database analyses reveal:

These data demonstrate that SLC13A4 expression generally decreases with increasing tumor malignancy, suggesting its potential utility as a prognostic biomarker. Researchers investigating HNSCC should consider SLC13A4 expression analysis as part of their comprehensive tumor characterization approach .

What methodologies are recommended for investigating SLC13A4's role in tumor immune microenvironment?

To investigate SLC13A4's relationship with the tumor immune microenvironment, researchers should employ a multi-modal approach:

• Transcriptomic analysis:

  • Utilize RNA-sequencing data from TCGA and other public databases

  • Apply CIBERSORT algorithm to estimate immune cell infiltration

  • Compare immune cell populations between high and low SLC13A4 expression groups using Wilcoxon test

• Functional correlation analysis:

  • Examine correlations between SLC13A4 expression and markers of T cell exhaustion

  • Analyze associations with specific immune cell populations (documented correlations include positive associations with neutrophils, plasma cells, T follicular helper cells, gamma delta T cells, regulatory T cells, and naive B cells)

  • Investigate negative correlations with monocytes, M1/M2 macrophages, resting CD4+ memory T cells, and NK cells

• Pathway enrichment analysis:

  • Perform Gene Set Enrichment Analysis (GSEA) using Molecular Signatures Database

  • Focus on KEGG, Hallmark, and immune signatures gene sets

  • Apply nominal p-value < 0.05 and FDR ≤ 25% as statistical thresholds

• Validation experiments:

  • Design co-culture experiments with immune and tumor cells

  • Manipulate SLC13A4 expression using siRNA or CRISPR techniques

  • Assess functional outcomes including cytokine production, immune cell activation, and tumor cell killing

This comprehensive approach enables researchers to establish mechanistic links between SLC13A4 expression and tumor immune responses .

How can gene expression databases be leveraged to investigate SLC13A4's role in various tumor types?

For comprehensive investigation of SLC13A4 across tumor types, researchers should implement a systematic database mining approach:

• Database selection and utilization:

  • TCGA: Access RNA-seq data across 32+ cancer types with matched clinical information

  • Oncomine: Analyze differential expression between tumor and adjacent normal tissues

  • TIMER: Evaluate immune cell infiltration correlations

  • Human Protein Atlas (HPA): Examine protein expression patterns through immunohistochemistry images

• Cross-validation methodology:

  • Compare SLC13A4 expression patterns across multiple databases

  • Validate findings using different statistical approaches

  • Integrate RNA and protein expression data

• Statistical analysis pipeline:

  • Apply Wilcoxon test for comparing tumor vs. normal expression

  • Use Fisher test to analyze relationships between expression and clinical characteristics

  • Implement univariate and multivariate Cox regression models to assess prognostic value

  • Generate survival curves (OS, DFS, PFS, DSS, RFS) using Kaplan-Meier method

• Visualization and interpretation:

  • Create comprehensive heatmaps of expression across cancer types

  • Generate forest plots for hazard ratios

  • Develop correlation matrices for immune cell populations

This approach has revealed SLC13A4's differential expression pattern across cancers, including decreased expression in HNSCC, esophageal cancer, and sarcoma, while showing increased expression in lymphoma, renal clear cell carcinoma, hepatocellular carcinoma, cholangiocarcinoma, and rectal adenocarcinoma .

What are the recommended protocols for conducting Gene Set Enrichment Analysis (GSEA) based on SLC13A4 expression?

To perform rigorous GSEA based on SLC13A4 expression, researchers should follow this detailed methodological framework:

• Data preparation:

  • Obtain RNA-sequencing data from TCGA or similar repositories

  • Normalize expression values using appropriate methods (e.g., FPKM, TPM)

  • Stratify samples into high and low SLC13A4 expression groups based on median expression

• Software and tools:

  • Download GSEA software (V4.0.2 or later) from the Broad Institute

  • Utilize R packages for supplementary analyses (R X64 4.0.0 and Bioconductor packages)

• Gene set selection:

  • Download relevant gene sets from Molecular Signatures Database:

    • KEGG pathways (cellular processes and molecular interactions)

    • Hallmark gene sets (well-defined biological states or processes)

    • Immune signatures (immune system functions and cells)

• Analysis parameters:

  • Set permutation type to "phenotype"

  • Set permutation number to 1000

  • Apply weighted enrichment statistic

  • Define significance thresholds: nominal p-value < 0.05 and FDR ≤ 25%

• Results interpretation:

  • Examine enrichment scores (ES) and normalized enrichment scores (NES)

  • Analyze leading-edge subsets to identify core genes driving enrichment

  • Create enrichment plots for significantly enriched pathways

Previous GSEA results have shown that genes in the SLC13A4 low-expression group are primarily enriched in immunity-related activities, viral diseases, typical tumor pathways, and metabolism, while the high-expression group demonstrates enrichment in metabolic pathways. This analytical approach provides critical insights into the biological mechanisms potentially influenced by SLC13A4 expression levels .

What are common challenges in SLC13A4 antibody applications and how can they be addressed?

Researchers working with SLC13A4 antibodies may encounter several technical challenges that can be systematically addressed:

• Non-specific binding in Western blots:

  • Problem: Multiple bands or high background

  • Solutions:

    • Increase blocking time (3-5% BSA for 2 hours)

    • Optimize primary antibody dilution (test range: 1:250-1:1000)

    • Add 0.1-0.5% Tween-20 to washing buffers

    • Pre-adsorb antibody with non-specific proteins

• Weak or absent signal in IHC:

  • Problem: Poor antigen detection despite correct tissue selection

  • Solutions:

    • Optimize antigen retrieval (test both citrate and EDTA buffers)

    • Extend primary antibody incubation (overnight at 4°C)

    • Utilize amplification systems (tyramide signal amplification)

    • Verify tissue fixation conditions (overfixation can mask epitopes)

• Inconsistent results across tissue types:

  • Problem: Variable staining patterns in different tissues

  • Solutions:

    • Adjust antibody concentration based on tissue type

    • Validate with multiple antibodies targeting different epitopes

    • Include positive control tissues (placenta, testis) in each experiment

    • Consider tissue-specific optimization of protocols

• Cross-reactivity concerns:

  • Problem: Potential binding to related sulfate transporters

  • Solutions:

    • Validate using knockout/knockdown models

    • Perform peptide competition assays

    • Compare results with orthogonal detection methods (qPCR, RNA-seq)

Implementing these troubleshooting strategies will enhance the reliability and reproducibility of SLC13A4 antibody applications in research settings .

How can researchers validate SLC13A4 antibody specificity in their experimental systems?

To ensure robust and reliable results, researchers should implement a comprehensive validation strategy for SLC13A4 antibodies:

• Multi-technique validation approach:

  • Western blot: Confirm band at expected molecular weight (69 kDa)

  • Immunoprecipitation followed by mass spectrometry: Definitively identify pulled-down protein

  • Immunocytochemistry: Compare localization with known subcellular distribution patterns

  • siRNA/shRNA knockdown: Demonstrate reduction/elimination of signal with target depletion

• Control experiments:

  • Positive controls: Include tissues/cells known to express SLC13A4 (placenta, testis, HEK-293T)

  • Negative controls: Use tissues/cells with minimal expression or after knockdown

  • Isotype controls: Apply matched isotype antibody at identical concentration

  • Peptide competition: Pre-incubate antibody with immunizing peptide to confirm specificity

• Cross-antibody verification:

  • Compare results using antibodies from different suppliers or clones

  • Test antibodies targeting different epitopes within SLC13A4

  • Correlate protein detection with mRNA expression data

• Functional validation:

  • Confirm that detected protein participates in sulfate transport

  • Verify that protein expression changes correlate with functional outcomes

  • Demonstrate physiological relevance through appropriate functional assays

This systematic validation approach ensures that experimental findings genuinely reflect SLC13A4 biology rather than technical artifacts or non-specific interactions .

What emerging applications might benefit from SLC13A4 antibody research?

Several promising research frontiers could benefit from advanced SLC13A4 antibody applications:

• Liquid biopsy development:

  • Investigate SLC13A4 as a circulating biomarker in cancer patients

  • Develop sensitive detection methods for SLC13A4 in blood or other bodily fluids

  • Correlate circulating levels with tumor burden and treatment response

• Targeted therapy approaches:

  • Utilize antibodies to develop SLC13A4-targeting therapeutic conjugates

  • Explore SLC13A4 as a potential portal for drug delivery to specific tissues

  • Investigate immune-modulating effects of targeting SLC13A4+ cells

• Single-cell analysis applications:

  • Apply SLC13A4 antibodies in mass cytometry or imaging mass cytometry

  • Characterize SLC13A4 expression at single-cell resolution in tumor microenvironments

  • Identify rare cell populations based on SLC13A4 expression patterns

• Functional imaging:

  • Develop labeled antibodies for non-invasive imaging of SLC13A4 distribution

  • Monitor treatment response through longitudinal imaging

  • Correlate imaging findings with clinical outcomes

Given SLC13A4's correlation with immune cell infiltration and clinical outcomes in multiple cancers, these emerging applications could significantly advance both diagnostic and therapeutic approaches in oncology .

How might researchers design experiments to resolve contradictions in SLC13A4 expression data across different cancer types?

To address discrepancies in SLC13A4 expression patterns across cancer types, researchers should implement a systematic experimental design:

• Standardized multi-cancer analysis protocol:

  • Select representative cell lines from cancers with contradictory SLC13A4 expression patterns

  • Apply identical experimental conditions for all cancer types

  • Utilize multiple detection methods (qPCR, Western blot, immunohistochemistry)

  • Quantify expression using standardized metrics and reference genes

• Context-dependent expression investigation:

  • Examine SLC13A4 expression under various conditions:

    • Normoxia vs. hypoxia

    • Different growth factor stimulations

    • Various differentiation states

    • Immune cell co-culture conditions

  • Correlate expression changes with functional outcomes in each cancer type

• Epigenetic and transcriptional regulation analysis:

  • Perform promoter methylation analysis across cancer types

  • Conduct ChIP-seq to identify differential transcription factor binding

  • Investigate microRNA regulation patterns

  • Analyze alternative splicing events affecting antibody epitope recognition

• Functional impact assessment:

  • Design CRISPR-mediated knockout experiments in multiple cancer types

  • Compare phenotypic consequences of SLC13A4 modulation across cancers

  • Measure effects on sulfate metabolism and related pathways

  • Assess impact on treatment response and immune infiltration

This comprehensive approach would help reconcile apparently contradictory findings, such as SLC13A4's downregulation in HNSCC, esophageal cancer, and sarcoma versus its upregulation in lymphoma, renal clear cell carcinoma, hepatocellular carcinoma, and rectal adenocarcinoma. Understanding these context-dependent differences would significantly advance our knowledge of SLC13A4's role in cancer biology .